Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
暂无分享,去创建一个
P. Geusens | D. M. van der Heijde | M. Boers | R. Landewé | D. Heinegård | S. Lohmander | J. Matyas | T. Saxne | P. Garnero | V. Kraus | H. El-Gabalawy | W. Maksymowych